Minireview

Multiomic candidate biomarkers for clinical manifestations of sickle cell severity: Early steps to precision medicine

Steven R. Goodman, Betty Sue Pace, Kirk C. Hansen, Angelo D’alessandro, Yang Xia, Ovidiu Daescu, Stephen J. Glatt

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

In this review, we provide a description of those candidate biomarkers which have been demonstrated by multiple-omics approaches to vary in correlation with specific clinical manifestations of sickle cell severity. We believe that future clinical analyses of severity phenotype will require a multiomic analysis, or an omics stack approach, which includes integrated interactomics. It will also require the analysis of big data sets. These candidate biomarkers, whether they are individual or panels of functionally linked markers, will require future validation in large prospective and retrospective clinical studies. Once validated, the hope is that informative biomarkers will be used for the identification of individuals most likely to experience severe complications, and thereby be applied for the design of patient-specific therapeutic approaches and response to treatment. This would be the beginning of precision medicine for sickle cell disease.

Original languageEnglish (US)
Pages (from-to)772-781
Number of pages10
JournalExperimental Biology and Medicine
Volume241
Issue number7
DOIs
StatePublished - Jan 1 2016

Fingerprint

Precision Medicine
Biomarkers
Medicine
Sickle Cell Anemia
Retrospective Studies
Phenotype
Therapeutics

Keywords

  • Genomics
  • interactomics
  • metabolomics
  • precision medicine
  • proteomics
  • sickle cell disease

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Minireview : Multiomic candidate biomarkers for clinical manifestations of sickle cell severity: Early steps to precision medicine. / Goodman, Steven R.; Pace, Betty Sue; Hansen, Kirk C.; D’alessandro, Angelo; Xia, Yang; Daescu, Ovidiu; Glatt, Stephen J.

In: Experimental Biology and Medicine, Vol. 241, No. 7, 01.01.2016, p. 772-781.

Research output: Contribution to journalArticle

Goodman, Steven R. ; Pace, Betty Sue ; Hansen, Kirk C. ; D’alessandro, Angelo ; Xia, Yang ; Daescu, Ovidiu ; Glatt, Stephen J. / Minireview : Multiomic candidate biomarkers for clinical manifestations of sickle cell severity: Early steps to precision medicine. In: Experimental Biology and Medicine. 2016 ; Vol. 241, No. 7. pp. 772-781.
@article{6e1dbfc408f04f3498b8a4f4564a0915,
title = "Minireview: Multiomic candidate biomarkers for clinical manifestations of sickle cell severity: Early steps to precision medicine",
abstract = "In this review, we provide a description of those candidate biomarkers which have been demonstrated by multiple-omics approaches to vary in correlation with specific clinical manifestations of sickle cell severity. We believe that future clinical analyses of severity phenotype will require a multiomic analysis, or an omics stack approach, which includes integrated interactomics. It will also require the analysis of big data sets. These candidate biomarkers, whether they are individual or panels of functionally linked markers, will require future validation in large prospective and retrospective clinical studies. Once validated, the hope is that informative biomarkers will be used for the identification of individuals most likely to experience severe complications, and thereby be applied for the design of patient-specific therapeutic approaches and response to treatment. This would be the beginning of precision medicine for sickle cell disease.",
keywords = "Genomics, interactomics, metabolomics, precision medicine, proteomics, sickle cell disease",
author = "Goodman, {Steven R.} and Pace, {Betty Sue} and Hansen, {Kirk C.} and Angelo D’alessandro and Yang Xia and Ovidiu Daescu and Glatt, {Stephen J.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1177/1535370216640150",
language = "English (US)",
volume = "241",
pages = "772--781",
journal = "Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)",
issn = "1535-3702",
publisher = "Society for Experimental Biology and Medicine",
number = "7",

}

TY - JOUR

T1 - Minireview

T2 - Multiomic candidate biomarkers for clinical manifestations of sickle cell severity: Early steps to precision medicine

AU - Goodman, Steven R.

AU - Pace, Betty Sue

AU - Hansen, Kirk C.

AU - D’alessandro, Angelo

AU - Xia, Yang

AU - Daescu, Ovidiu

AU - Glatt, Stephen J.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - In this review, we provide a description of those candidate biomarkers which have been demonstrated by multiple-omics approaches to vary in correlation with specific clinical manifestations of sickle cell severity. We believe that future clinical analyses of severity phenotype will require a multiomic analysis, or an omics stack approach, which includes integrated interactomics. It will also require the analysis of big data sets. These candidate biomarkers, whether they are individual or panels of functionally linked markers, will require future validation in large prospective and retrospective clinical studies. Once validated, the hope is that informative biomarkers will be used for the identification of individuals most likely to experience severe complications, and thereby be applied for the design of patient-specific therapeutic approaches and response to treatment. This would be the beginning of precision medicine for sickle cell disease.

AB - In this review, we provide a description of those candidate biomarkers which have been demonstrated by multiple-omics approaches to vary in correlation with specific clinical manifestations of sickle cell severity. We believe that future clinical analyses of severity phenotype will require a multiomic analysis, or an omics stack approach, which includes integrated interactomics. It will also require the analysis of big data sets. These candidate biomarkers, whether they are individual or panels of functionally linked markers, will require future validation in large prospective and retrospective clinical studies. Once validated, the hope is that informative biomarkers will be used for the identification of individuals most likely to experience severe complications, and thereby be applied for the design of patient-specific therapeutic approaches and response to treatment. This would be the beginning of precision medicine for sickle cell disease.

KW - Genomics

KW - interactomics

KW - metabolomics

KW - precision medicine

KW - proteomics

KW - sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=84963593336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963593336&partnerID=8YFLogxK

U2 - 10.1177/1535370216640150

DO - 10.1177/1535370216640150

M3 - Article

VL - 241

SP - 772

EP - 781

JO - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)

JF - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)

SN - 1535-3702

IS - 7

ER -